(Poly)peptide-based therapy for diabetes mellitus: Insulins versus incretins

Life Sciences

Volumn 99, Issue 1-2, 2014, Pages 7-13

  Bavec, Aljoša ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Diabetes; Glucagon like peptide 1 mimetics; Incretins; Insulin analogues; Peptide drugs

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; CJC 1134 PC; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN PEGLISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIG INSULIN; POLYPEPTIDE; SEMAGLUTIDE; TASPOGLUTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DIET RESTRICTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN DEGRADATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT RESPONSE;

DIABETES; GLUCAGON LIKE PEPTIDE-1 MIMETICS; INCRETINS; INSULIN ANALOGUES; PEPTIDE DRUGS;

DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULINS; PEPTIDES;

EID: 84896719794     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.12.210     Document Type: Review

References (65)

1. B. Ahrén GLP-1 for type 2 diabetes Exp Cell Res 317 2011 1239 1245
2. C. Alves, F. Batel-Marques, and A.F. Macedo A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Diabetes Res Clin Pract 98 2 2012 271 284
3. Anon Global status report on noncommunicable diseases 2010 2011 World Health Organization Geneva
4. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
5. W. Bao, K. Aravindhan, H. Alsaid, T. Chendrimada, M. Szapacs, and D.R. Citerone et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency PLoS One 6 8 2011 e23570
6. A.H. Barnett The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide Diabetes Obes Metab 14 4 2012 304 314
7. A. Bavec Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2 Acta Chim Slov 60 2 2013 237 242
8. R.H. Becker, and A.D. Frick Clinical pharmacokinetics and pharmacodynamics of insulin glulisine Clin Pharmacokinet 47 2008 7 20
9. J. Brange, U. Ribel, J.F. Hansen, G. Dodson, M.T. Hansen, and S. Havelund et al. Monomeric insulins obtained by protein engineering and their medical implications Nature 333 1988 679 682
10. D.N. Brems, L.A. Alter, M.J. Beckage, R.E. Chance, R.D. Dimarchi, and L.K. Green et al. Altering the association of insulin by amino acid replacement Protein Eng 5 1992 527 533
11. J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, and C.R. Heilmann et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
12. J. Buse, T. Vilsbøll, J. Thurman, T. Blevins, I.H. Langbakke, and L.H. Damgaard et al. Liraglutide contributes significantly to glycaemic control achieved in IDegLira: a double-blind Phase 3 trial in type 2 diabetes Oral presentation (OP - 0082) at the World Diabetes Congress for the International Diabetes Federation (IDF), 3 December 2013 2013
13. B. Charbonnel, A. Schweizer, and S. Dejager Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract (1995) 41 2 2013 93 107
14. M. Christensen Knop FK once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diab Rep 10 2 2010 124 132
15. W. Creutzfeldt The entero-insular axis in type 2 diabetes: incretins as therapeutic agents Exp Clin Endocrinol Diabetes 109 2001 S288 S303
16. Risto S. Cvetković, and Greg L. Plosker Exenatide, a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) Drugs 67 6 2007 935 954
17. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, and C.J. Paciorek et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 9785 2011 31 40
18. G. Derosa, I.G. Franzetti, F. Querci, A. Carbone, L. Ciccarelli, and M.N. Piccinni et al. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes Diabet Med 29 2012 1515 1523
19. M.B. DeYoung, L. MacConell, V. Sarin, M. Trautmann, and P. Herbert Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 13 2011 1145 1154
20. M.E. Doyle, and J.M. Egan Pharmacological agents that directly modulate insulin secretion Pharmacol Rev 55 2003 105 131
21. D.J. Drucker Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 30 2007 1335 1343
22. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
23. J. Eng, W.A. Kleinman, L. Singh, G. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 267 1992 7402 7405
24. M. Evans, P.M. Schumm-Draeger, J. Vora, and A.B. King A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations Diabetes Obes Metab 13 2011 677 684
25. G.P. Fadini, N. Simioni, V. Frison, M. Dal Pos, M. Bettio, and P. Rocchini et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients Acta Diabetol 2013 10.1007/s00592-013-0489-3
26. V.A. Gault, B.D. Kerr, P. Harriott, and P.R. Flatt Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity Clin Sci (Lond) 121 3 2011 107 117
27. S.C.L. Gough, S. Harris, V. Woo, and M. Davies Insulin degludec: overview of a novel ultra long-acting basal insulin Diabetes Obes Metab 15 2013 301 309
28. R.J. Heine, L.F. Van Gaal, D. Johns, M.J. Mihm, M.H. Widel, and R.G. Brodows Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 143 2005 559 569
29. L. Heinemann, C. Weyer, M. Rauhaus, S. Heinrichs, and T. Heise Variability of the metabolic effect of soluble insulin and the rapid acting insulin analog insulin aspart Diabetes Care 21 1998 1910 1914
30. T. Heise, C.J. Tack, R. Cuddihy, J. Davidson, D. Gouet, and A. Liebl et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial Diabetes Care 34 3 2011 669 674
31. S. Heller, P. Kozlovski, and P. Kurtzhals Insulin's 85th anniversary - an enduring medical miracle Diabetes Res Clin Pract 78 2007 149 158
32. A.M. Hennige, V. Strack, E. Metzinger, G. Seipke, H.U. Haring, and M. Kellerer Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors Diabetologia 48 2005 1891 1897
33. M. Hompesch, S.M. Ocheltree, E.T. Wondmagegnehu, L.A. Morrow, A.P. Kollmeier, and B.N. Campaigne et al. Pharmacokinetics and pharma-codynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes Curr Med Res Opin 25 2009 2679 2687
34. K. Horvath, K. Jeitler, A. Berghold, Sh. Ebrahim, T. Gratzer, and J. Plank et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus Cochrane Database Syst Rev 18 2 2007 CD005613
35. D.C. Howey, R.R. Bowsher, R.L. Brunelle, and J.R. Woodworth [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin Diabetes 43 1994 396 402
36. K. Huang, S.J. Chan, Q.X. Hua, Y.C. Chu, R.Y. Wang, and B. Klaproth et al. The A-chain of insulin contacts the insert domain of the insulin receptor. Photo-cross-linking and mutagenesis of a diabetes-related crevice J Biol Chem 282 48 2007 35337 35349
37. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, and N.P. Jones et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
38. B.D. Kerr, N. Irwin, F.P. O'Harte, C.J. Bailey, P.R. Flatt, and V.A. Gault Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties Biochem Pharmacol 78 2009 1008 1016
39. P. Kurtzhals Pharmacology of insulin detemir Endocrinol Metab Clin North Am 36 Suppl. 1 2007 14 20
40. I. Jonassen, S. Havelund, T. Hoeg-Jensen, D.B. Steensgaard, P.O. Wahlund, and U. Ribel Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin Pharm Res 29 2012 2104 2114
41. P. Kurtzhals, L. Schaffer, A. Sorensen, C. Kristensen, I. Jonassen, and C. Schmid et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 2000 999 1005
42. S. Matthaei, M. Stumvoll, M. Kellerer, and H.U. Häring Pathophysiology and pharmacological treatment of insulin resistance Endocr Rev 21 2000 585 618
43. V. McAulay, and B.M. Frier Insulin analogues and other developments in insulin therapy for diabetes Expert Opin Pharmacother 4 2003 1141 1156
44. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 124 2011 S3 S18
45. M.A. Nauck, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert, and W. Creutzfeldt Preserved incretin activity of glucagon-like 6Q8277 peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide 688 in patients with type-2 diabetes mellitus J Clin Invest 91 1993 301 307
46. M.A. Nauck, J.R. Petrie, G. Sesti, E Mannucci, JP Courreges, and S Atkin et al. The once-weekly human GLP1 analogue semaglutide provides significant reductions in HbA1c and bodyweight in patients with Type 2 diabetes Presented at: 48th EASD Annual Meeting. Berlin, Germany, 1-5 October 2012 2012
47. M. Nauck, A. Frid, K. Hermansen, A.B. Thomsen, M. During, and N. Shah et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. 11 Diabetes Obes Metab 15 3 2013 204 212
48. J.J. Neumiller, T.E. Sonnett, L.D. Wood, S.M. Setter, and R.K. Campbell Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes Diabetes Metab Syndr Obes 3 2010 215 226
49. E. Nishimura, A.R. Sørensen, B.F. Hansen, C.E. Stidsen, G.S. Olsen, and L. Schäffer et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential Diabetologia 53 Suppl. 1 2010 S388 S389
50. R. Padwal, S.R. Majumda, J.A. Johnson, J Varney, and FA McAlister A systematic review of drug therapy to delay or prevent type 2 diabetes Diabetes Care 28 2005 736 744
51. R. Perfetti Combining basal insulin analogs with glucagon-like peptide-1 mimetics Diabetes Technol Ther 13 9 2011 873 881
52. A.B. Petersen, and M. Christensen Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus Diabetes Metab Syndr Obes 6 2013 217 231
53. J. Plank, A. Wutte, G. Brunner, A. Siebenhofer, B. Semlitsch, and R. Sommer et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes Diabetes Care 25 2002 2053 2057
54. I. Raz, M. Hanefeld, L. Xu, C. Caria, D. Williams-Herman, and H. Khatami Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2006 2564 2571
55. J. Rosenstock, B. Balas, B. Charbonnel, G.B. Bolli, M. Boldrin, and R. Ratner et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial Diabetes Care 36 3 2013 498 504
56. S. Schwartz, and R.A. DeFronzo Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: the time has come for GLP-1 receptor agonists! Diabetes Care 36 7 2013 2107 2111
57. L. Sciacca, R. Le Moli, and R. Vigneri Insulin analogs and cancer Front Endocrinol (Lausanne) 3 2012 21
58. D. Singh-Franco, A. Perez, and C. Harrington The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis Diabetes Obes Metab 13 2 2011 169 180
59. M. Stumvoll, B.J. Goldstein, and T.W. van Haeften Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 2005 1333 1346
60. N. Tennagels, and U. Werner The metabolic and mitogenic properties of basal insulin analogues Arch Physiol Biochem 119 1 2013 1 14
61. B. Thorens, A. Porret, L. Bühler, S.P. Deng, P. Morel, and C. Widmann Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 42 1993 1678 1682
62. G.E. Umpierrez, and M. Korytkowski Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: insulin therapy has proven itself and is considered the mainstay of treatment Diabetes Care 36 7 2013 2112 2117
63. G.E. Umpierrez, T. Blevins, J. Rosenstock, C. Cheng, J.H. Anderson, and E.J. Bastyr III et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study Diabetes Obes Metab 13 5 2011 418 425
64. J.F. Yale, G. Bakris, B. Cariou, D. Yue, E. David-Neto, and L. Xi et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 5 2013 463 473
65. B. Zinman Newer insulin analogs: advances in basal insulin replacement Diabetes Obes Metab 15 Suppl. 1 2013 6 10